Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Reexamination Certificate
2003-03-04
2008-10-14
Canella, Karen A (Department: 1643)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
C424S135100, C424S138100, C424S155100, C424S156100
Reexamination Certificate
active
07435412
ABSTRACT:
The preparation and characterization of antibodies that bind to antigens on CLL or other cancer cells, especially to antigens upregulated in the cancer cells, and the identification and characterization of antigens present on or upregulated by cancer cells are useful in studying and treating cancer.
REFERENCES:
patent: 3940475 (1976-02-01), Gross
patent: 4289747 (1981-09-01), Chu
patent: 4376110 (1983-03-01), David et al.
patent: 5223409 (1993-06-01), Ladner et al.
patent: 5225539 (1993-07-01), Winter
patent: 5403484 (1995-04-01), Ladner et al.
patent: 5427908 (1995-06-01), Dower et al.
patent: 5434131 (1995-07-01), Linsley et al.
patent: 5508717 (1996-04-01), Miller
patent: 5571698 (1996-11-01), Ladner et al.
patent: 5580717 (1996-12-01), Dower et al.
patent: 5780279 (1998-07-01), Matthews et al.
patent: 5916560 (1999-06-01), Larsen et al.
patent: 6011138 (2000-01-01), Reff et al.
patent: 6040136 (2000-03-01), Garrard et al.
patent: 6338851 (2002-01-01), Gorczynski
patent: 6652858 (2003-11-01), Gorczynski et al.
patent: 6749854 (2004-06-01), Gorczynski et al.
patent: 6955811 (2005-10-01), Gorczynski et al.
patent: 6984625 (2006-01-01), Gorczynski
patent: 7238352 (2007-07-01), Gorczynski et al.
patent: 2002/0031515 (2002-03-01), Caliguira et al.
patent: 2002/0168364 (2002-11-01), Gorczynski et al.
patent: 2002/0192215 (2002-12-01), Hoek et al.
patent: 2003/0017491 (2003-01-01), Shi et al.
patent: 2004/0018972 (2004-01-01), Gorczynski et al.
patent: 2004/0054145 (2004-03-01), Gorczynski
patent: 2004/0175692 (2004-09-01), Bowdish et al.
patent: 2004/0198661 (2004-10-01), Bowdish et al.
patent: 2005/0048069 (2005-03-01), Gorczynski et al.
patent: 2005/0107214 (2005-05-01), Gorczynski et al.
patent: 2005/0129690 (2005-06-01), Bowdish et al.
patent: 2005/0169870 (2005-08-01), Truitt et al.
patent: WO-8403508 (1984-09-01), None
patent: WO-8503508 (1985-08-01), None
patent: WO-8806630 (1988-09-01), None
patent: WO-9215679 (1992-09-01), None
patent: WO-9428027 (1994-12-01), None
patent: WO 95/18825 (1995-07-01), None
patent: WO-9627011 (1996-09-01), None
patent: WO 96/38557 (1996-12-01), None
patent: WO-9708320 (1997-03-01), None
patent: WO-9721450 (1997-06-01), None
patent: WO-9721450 (1997-06-01), None
patent: WO-9924565 (1999-05-01), None
patent: WO-0211762 (2002-02-01), None
patent: WO-02/059280 (2002-08-01), None
patent: WO-02095030 (2002-11-01), None
patent: WO-03025202 (2003-03-01), None
patent: WO-2004078937 (2004-09-01), None
patent: WO-04078938 (2004-10-01), None
Kneitz et al (Leukemia, 1999, vol. 13, pp. 98-104).
Auchincloss, “Strategies to Induce Tolerance,” Transplantation Immunology, Bach and Auchincloss, Eds., Wiley-Liss, New York, Chapter 11, pp. 211-218 (1995).
Barclay, “Different reticular elements in rat lymphoid tissue identified by localization of Ia, Thy-1 and MRC OX 2 antigens,” Immunology, 44:727-736(1981).
Barclay and Ward, “Purification and Chemical Characterisation of Membrane Glycoproteins From Rat Thymocytes and Brain, Recognised by Monoclonal Antibody MRC OX2,” European J. Biochemistry, 129:447-458(1982).
Borriello et al., “Characterization and localization of Mox2, the gene encoding the murine homolog of the rat MRC OX—2 membrane glycoprotein,” Mammalian Genome, 9(2):114-118 (1998).
Borriello et al., “MRC OX-2 Defines a Novel T Cell Costimulatory Pathway,” J. Immunol., 158:4549-4554(1997).
Chen et al., “Cloning and characterization of the murine homologue of the rat/human MRC OX—2 gene,” Biochemica et Biophysica Acta, 1362(1):6-10(1997).
Gorczynski et al., “Increased expression of the novel molecule OX—2 is involved in prolongation of murine renal allograft survival,” Transplantation, 65(8):1106-1114(1998).
Gorczynski et al., “An Immunoadhesin incorporating the Molecule OX-2 is a Potent Immunosuppressant That Prolongs Allo- and Xenograft Survival,” J. Immunol., 163:1654-1660(1999).
Preston et al., “The leukocyte
euron cell surface antigen OX2 binds to ligand on macrophages”, European J. of Immunol., 27(8):1911-1918(1997).
Bach, “Immunosuppressive therapy of autoimmune diseases,” Immunology Today, 14(6)322-326(1993).
Bohen, S.P., “Variation in gene expression patterns in follicular lymphoma and the response to rituximab,” PNAS, 100(4):1926-1930(2003).
Boon, Thierry., “Toward a Genetic Analysis of Tumor Rejection Antigens,” Advances in Cancer Res., 58: 177-210(1992).
Broderick et al., “Constitutive Retinal CD200 Expression Regulates Resident Microglia and Activin State of Inflammatory Cells During Experimental Autoimmune Uveoretinitis,” Am. J. of Pathology, 161(5):1669-1677(2002).
Clark, D.A., “Intralipid as Treatment for Recurrent Unexplained Abortion?”, Am. J. of Reprod. Immunol., 32:290-293(1994).
Clark et al., Amer. Soc. for Reprod. Medicine, 55th Annual Meeting (1999). Abstract Only.
Clark et al., “The OX-2 Tolerance Signal Molecule at the Fetomaternal Interface Determines Pregnancy Outcome,” Amer. Journal of Reprod Immunol., 43:326(2000). Abstract Only.
Chaouat and Clark, FAS/FAS Ligand Interaction at the Placental Interface is not Required for the Success of Allogeneic Pregnancy in Anti-Paternal MHC Preimmunized Mice, Presented at the 6th Congress of the Adria-Alps Soc. of Immunol. of Reprod., (2000) / Amer. J. of Reprod. Immunol., 45:108-115(2001).
Clark et al., “Fg12 prothrombinase expression in mouse trophoblast and decidua triggers abortion but may be countered by OX-2,” Mol. Human Reprod., 7-185-194(2001).
Cohen, P.L., “Systemic Autoimmunity,” in Fundamental Immunology, Fourth edition, W.E. Paul, Editor, Lippincott-Raven Publishers, Philadelphia, Ch. 33, p. 1067-1088(1999).
Dick et al., “Control of Myeloid Activity During Retinal Inflammation,” J. of Leukocyte Bio., 74:161-166(2003).
Gorczynski et al., “Does Successful Allopregnancy Mimic Transplantation Tolerance?”, Graft, 4(5):338-345(2001).
Hoek, et al., “Down-Regulation of the Macrophage Lineage Through Interaction with OX2 (CD200),” Science, 290:1768-1771(2000).
Huang, “Structural chemistry and therapeutic intervention of protein-protein interactions in immune response, human immunodeficiency virus entry, and apoptosis,” Pharmacol. Therapeutics, 86:201-215(2000).
Jain, “The next frontier of molecular medicine: Delivery of therapeutics,” Nature Medicine, 4(6):655-657(1998).
Keil et al., American Society for Reproductive Immunology XXIst Annual Meeting, Jun. 9-12, 2001, Chicago, IL., p. 343, Abstract Only.
Kim et al., “Divergent Effects of 4-1BB Antibodies on Antitumor Immunity and on Tumor-reactive T-Cell Generation,” Cancer Res., 61:2031-2037(2001).
Kjaergaard et al., “Therapeutic Efficacy of OX-40 Receptor Antibody Depends on Tumor Immunogenicity and Anatomic Site of Tumor Growth,” Cancer Res. 60:5514-5521(2000).
Pardoll, Drew., “Therapeutic Vaccination for Cancer,” Clin. Immunol., 95(1):S44-S62(2000).
Ragheb et al., “Preparation and functional properties of monoclonal antibodies to human, mouse and rat OX-2”, Immunol. Letters, 68:311-315(1999).
Romagnani, Sergio., “Short Analytical Review: TH1 and TH2 in Human Diseases,” Clin. Immunol. Immunopath, 80(3):225-235(1996).
RosenWald et al., “Relation of Gene Expression Phenotype to Immunoglobulin Mutation Genotype in B Cell Chronic Lymphocytic Leukemia,” J. of Exp. Medicine, 194(11):1639-1647(2001).
Steinman, Lawrence., “Assessment of Animal Models for MS and Demyelinating Disease in the Design of Rational Therapy,” Neuron, 24:511-514(1999).
Tangri and Raghupathy, “Expression of Cytokines in Placentas of Mice Undergoing Immunologically Mediated Spontaneous Fetal Resorptions,” Biology of Reprod., 49:850-856(1993).
Toder et al., “Mouse Model for the Treatment of Immune Pregnancy Loss,” Am. J. of
Bowdish Katherine S.
McWhirter John
Alexion Pharmaceuticals, Inc.
Canella Karen A
Ropes & Gray LLP
LandOfFree
Chronic lymphocytic leukemia cell line does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Chronic lymphocytic leukemia cell line, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Chronic lymphocytic leukemia cell line will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4017015